Kagocel tablets 12mg №10×2

Name:
Kagocel
Description:
Tablets from white with a brownish tint to light brown, round biconvex with brown patches. Release form Tablets, 12 mg. 10 tablets in a blister pack made of PVC / PVDC film (polyvinyl chloride / polyvinylidene chloride – PVC / PVDC) and aluminum foil with a heat sealable coating. 1, 2 or 3 blisters, together with instructions for use, are placed in a cardboard pack. Dosage 12 mg Special instructions Due to the immaturity of the swallowing reflex in children under 6 years of age, it may be difficult to swallow solid dosage forms, which is associated with an increased risk of aspiration. It is necessary to take into account the individual characteristics of the child and take precautions when using Kagocel tablets in children under 6 years of age. To achieve a therapeutic effect, the drug should be started no later than the fourth day from the onset of the disease. Pharmacodynamics The mechanism of action of the drug Kagocel is determined by its ability to induce the production of interferons. Kagocel stimulates the interferon response of the late phase (24-48 hours), accompanied by an increase in the content of type I / II interferons in the body, which have high antiviral activity and provide immune protection against a viral infectious agent. When ingesting a single dose of Kagocel, the titer of interferons in the blood serum reaches its maximum values after 48 hours. At the same time, in the intestinal tissues, the maximum production of interferons is observed after 4 hours. The body’s immune response to the administration of Kagocel is characterized by a prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The drug Kagocel, when prescribed in therapeutic doses, is non-toxic, does not accumulate in the body. In studies in animals, no mutagenic, teratogenic, carcinogenic and embryotoxic properties of Kagocel were revealed. The effect of Kagocel on fertility (in particular, on spermatogenesis) in humans has not been studied. In long-term animal studies, no effect of the drug on the reproductive properties of both males and females was revealed. The greatest efficiency in the treatment with Kagocel is achieved when it is administered no later than the 4th day from the onset of an acute infection. For prophylactic purposes, the drug can be used at any time, including immediately after contact with the infectious agent. Pharmacokinetics 24 hours after administration, Kagocel accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentration is observed in adipose tissue, heart, muscles, testicles, brain, blood plasma. The low content of kagocel in the brain is explained by the high molecular weight of the drug, which makes it difficult to penetrate the blood-brain barrier. In plasma, the drug is found predominantly in bound form. With daily repeated administration of Kagocel, the volume of distribution varies widely in all organs studied. The accumulation of the drug in the spleen and lymph nodes is especially pronounced. When taken orally, about 20% of the administered dose of the drug enters the general circulation. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids – 47%, with proteins – 37%. The unbound portion of the drug is about 16%. Withdrawal: the drug is excreted from the body mainly through the intestines: 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestines and 10% through the kidneys. The drug was not detected in exhaled air. Indications for use Kagocel is used in adults and children over 3 years of age as a prophylactic and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a remedy for herpes in adults. Method of administration and doses For oral administration. For the treatment of influenza and SARS, adults are prescribed in the first two days – 2 tablets 3 times a day, in the next two days – one tablet 3 times a day. Total for the course – 18 tablets, course duration – 4 days. Prevention of influenza and SARS in adults is carried out in 7-day cycles: two days – 2 tablets 1 time per day, 5 days break, then repeat the cycle. The duration of the prophylactic course is from one week to several months. For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. Total for the course – 30 tablets, course duration – 5 days. For the treatment of influenza and SARS, children aged 3 to 6 years are prescribed in the first two days – 1 tablet 2 times a day, in the next two days – one tablet 1 time per day. Total for the course – 6 tablets, the duration of the course – 4 days. For the treatment of influenza and acute respiratory viral infections, children aged 6 years and older are prescribed in the first two days – 1 tablet 3 times a day, in the next two days – one tablet 2 times a day. Total for the course – 10 tablets, course duration – 4 days. Prevention of influenza and SARS in children aged 3 years and over is carried out in 7-day cycles: two days – 1 tablet 1 time per day, 5 days break, then repeat the cycle. The duration of the prophylactic course is from one week to several months. If there is no improvement after treatment, or symptoms worsen, or new symptoms appear, you should consult your doctor. Use the drug only according to the indications, the method of application and in the doses indicated in the instructions. Use during pregnancy and lactation Due to the lack of necessary clinical data, the drug is contraindicated during pregnancy and during breastfeeding (see section “Contraindications”). PrecautionsInfluence on the ability to drive vehicles, mechanisms The effect of the drug on the ability to drive vehicles, mechanisms has not been studied. Interaction with other drugs Kagocel is well combined with other antiviral drugs, immunomodulators and antibiotics (additive effect). Contraindications – Pregnancy and breastfeeding period; – Age up to 3 years; – Hypersensitivity to the components of the drug; – Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Composition Active ingredient: kagocel (in terms of dry matter) – 12 mg. Excipients: potato starch – 10 mg, calcium stearate – 0.65 mg, Ludipress (composition: lactose monohydrate – from 91% to 95%, povidone (Kollidon 30) – from 3.0% to 4.0%, crospovidone ( Kollidon CL) – from 3.0% to 4.0%) – to obtain a tablet weighing 100 mg. Overdose In case of accidental overdose, it is recommended to prescribe plenty of fluids and induce vomiting. Side effects Possible development of allergic reactions. If any of the side effects listed in the instructions get worse, or if you notice any other side effects not listed in the instructions, tell your doctor. Storage conditions In a place protected from light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Shelf life 4 years. After the expiration date indicated on the package, the drug should not be used. Buy Kagocel tablets 12mg №10×2 Price for Kagocel tablets 12mg №10x2Instruction for use for Kagocel tablets 12mg №10×2